Private equity firms are pouring capital into orthopedic care, with 6 deals closed in recent months by major PE players including Archimed, Cinven, Gemspring and InTandem. The sector’s appeal stems from surging, growing demand, particularly among aging populations, and a marked shift of services from hospitals to outpatient settings like ambulatory surgery centers.

That demand is fueling momentum across product developers, manufacturers and suppliers in the orthopedic space, with six total transactions closed to date. Cinven views the segment as a stable, resilient corner of medtech, with select areas of high innovation that improve patient outcomes and drive attractive growth, per Julia Kahr, the firm’s partner and head of its North America regional team.

Private equity’s push into orthopedics reflects a bet on the sector’s core durability amid broader medtech volatility. Outpatient care delivery cuts overhead costs for providers while meeting patient preference for convenient, lower-cost services, creating predictable cash flows that appeal to buyout firms and institutional investors seeking long-term steady, inflation-resistant returns. This stability sets orthopedics apart from riskier medtech subsectors.